About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 


Sign up to stay informed--receive email notifications for this journal

Industrial Biotechnology

Co-Editors-in-Chief: Glenn E. Nedwin, PhD, MoT and Larry P. Walker, PhD

ISSN: 1550-9087 • Published Bimonthly • Online ISSN: 1931-8421

Current Volume: 10

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Industrial Biotechnology manuscripts for peer-review may be submitted online at http://mc.manuscriptcentral.com/indbiotech


    Industrial Biotechnology is the only journal dedicated to bioresearch for industrial and environmental applications, bridging early-stage R&D with commercialization for sustainable, cost-and eco-efficient production of chemicals, materials, consumer goods, and energy. 

    Industrial Biotechnology presents critical contributions to the scientific literature in chemistry, biology, biochemistry, and engineering, through stringently peer-reviewed Original Research (§2, 3), Short Communications (§10), Reviews (§11), Methods (§12), and Technical Notes (§13). 

    The Journal’s broad coverage spans the entirety of the industrial biotechnology field, presenting breaking developments in R&D and applied biotechnology for applications including bioenergy and biofuels, biomass, biorefineries, pulp and paper, textiles, food, beverage, and feed processing, detergents, synthetic biology, biodefense, nanobiotechnology; bioremediation, biomaterials (biofilms, biopolymers), and industrial enzymes.

    Supplementing our peer-reviewed contributions is the Journal’s industry trade editorial content, including expert Feature Commentary (§14), industry, institute, and government Reports (§15), and News Updates on industrial biotech R&D and business developments (for News, e-mail press releases to vglaser@liebertpub.com). 

    Key Instructions & Overview
    (Comprehensive instructions in subsequent sections)

    2.1 Manuscripts submitted to the Journal must not be under consideration elsewhere (§8) and will be considered copyrighted to Mary Ann Liebert, Inc., publishers, and GEN Publishing, Inc., once accepted.
               2.1.1. A Letter of Transmittal should accompany each peer-review submission (§3.3).
              2.1.2. A completed Manuscript Submission and Copyright Agreement Form is required on acceptance (§8).

    2.2 Submissions for peer-review must be submitted electronically, online, at

    http://mc.manuscriptcentral.com/indbiotech.  See §3.1)

    2.3 High-resolution artwork files must be uploaded as separate files from the manuscript. Illustrations should only be included within text documents to indicate placement. Artwork must be in EPS or TIFF format, and in CMYK (not RGB; see §4). Word, PowerPoint, and Excel files must be converted; non-digital images should be scanned (§4.8).

    2.4 References must adhere to the citation style outlined in §6. 

    2.5 Manuscripts including reproduced data, text, etc., from previously copyrighted materials must be accompanied by permission of the other journal, book, or publisher/producer concerned. 


    3.1  All manuscripts for peer-review are to be submitted electronically online through Industrial Biotechnology’s web-based manuscripts service, Manuscript Central (http://mc.manuscriptcentral.com/indbiotech). New authors must Create an Account through link at uppermost top-right. Returning authors, log in only.  Manuscript Central will then guide authors step-by-step through the online submission process. 

    3.2. Electronic manuscripts should be formatted double-spaced, with margins of 1" (one inch) on each side and ample space on top and bottom. 

    3.3. An accompanying Cover Letter of Transmittal should state that:
    • the work has not previously been published
    • the work is not under consideration for publication elsewhere
    • all authors have read and agree with the contents of the submission
    • each author, if there are multiple authors, has contributed substantially to the work 


    4.1. Electronic submission of art is required through Manuscript Central. Guidelines in sections 4.2 through 4.9 must be followed. Note in particular Industrial Biotechnology’s requirements for image file formats (§4.3, §4.8), color (§4.3), resolution (§4.4), and pre-submission verification (§4.9). 

    4.2. Do not include publishable illustrations as part of the manuscript text file. Artwork should not be included within the text document except to show placement and facilitate editors’ ensuring of accuracy. 

    4.3. Image file format
    Images should be in high-resolution TIFF or EPS formats, each sent in separate files clearly labeled (“AuthorSurname-Figure X.tif” or “AuthorSurname-Figure X.eps”). Do NOT submit  JPEG files.  Color art must be saved as CYMK not RGB; all RGB files will be converted to CYMK, which can introduce color variation. 

    4.4. Image file resolution
    Line illustrations must be minimum 1,200 dpi at a picture width of 4". Half-tone and color photos should be at a minimum of 300 dpi at a picture width of 4". 

    4.5. Content
    Do not repeat information stated in the text. Do not create tables for data that can be or is explained concisely in the text. Provide titles for each tables. Define all acronyms in table footnotes, designated using superscript letters unless continuous with the main manuscript’s footnotes. Neither names nor logos of manufacturers or commercial suppliers should be included in tables or figures, excepting names in tables dedicated to highlighting relevant suppliers for a particular editorial theme. 

    4.6. Numbering
    Use Arabic numerals to number tables. Figures should be numbered in the order cited in the text. A listing of all figure titles should be submitted with each manuscript, either as a page within the manuscript, or in a separate file named “AuthorSurname-FigureList.doc”. 

    4.7. Legends and captions
    A legend or caption should be supplied for each illustration, all compiled in one common file. All symbol definitions should appear in a separate figure legend, not as a key within the figure. Legends should be numbered consecutively (Arabic numerals) and included on a separate page within the manuscript or a separate Word file (named “AuthorSurname-Captions.doc”). 

    4.8. Preparation of images
    Adobe is the preferred software platform for images. Images prepared in PowerPoint, Excel, or Word should NOT be submitted (See §4.8.1 to convert these). Logos are not permitted in figures. 

    4.8.1 To convert Word or Excel image files, SCAN these by the following guidelines:
    • Scan image at 100% size
    • Resolution should be set to 300 dpi
    • Final color mode should be CMYK. (See §4.3)
    • File should be saved as TIFF or EPS. (See §4.3) 

    4.8.2 To convert PowerPoint slide images:
    See www.liebertpub.com/MEDIA/pdf/ppconvert.pdf

    A spell-check of the entire document should be run, using U.S. spellings. Manuscript sections should appear in the following sequence, as delineated below: 

    5.1. Title page must contain: 

    * Complete title of the paper
    * For each author:
           - Full name (including first name and middle name/initial, if any)
           - Mailing address
           - Contact information (telephone, fax, and e-mail address)
           - Affiliations (institute/company)
    * Brief running title
    * Corresponding author’s complete contact information, including full mailing and e-mail address 

    5.2. Length
    Manuscripts should generally be between 2,500 and 3,500 words, excluding references and abstract. 

    5.3. Title
    Concisely describe the technology platform/scientific discovery. Refrain from use of “Novel” or “New”. Significance or application may be briefly described in a subtitle. 

    5.4. Abstract
    250 words or fewer. No subheadings. References not permitted in abstracts. 

    5.5. Introduction
    Summarize background, significance, and novelty. No discussion of results should be included in the Introduction. 

    5.6. Materials and Methods
    Sources of specific materials (including reagents, software, and instrumentation) should be stated and marked with ™ or ® if they are trademarked or registered, respectively. These marks should be included only at the product’s first mention within the body text. When citing specific brand names of products or technologies, please include in parentheses the manufacturer’s name and location (city, state/province, and, if outside the U.S., country). All acronyms and their definitions should be spelled out in a separate list on a page appearing immediately after the title page. Use only acronyms in text. 

    5.7. Results, Discussion
    Results and Discussion in shorter papers may be combined into one section. 

    5.8. Acknowledgments
    If relevant

    5.9  Disclosure Statement 
    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."

    5.10. References
    See §6 below 


    All references must be cited in the text using a superscript Arabic number, placed after any relevant punctuation within the phrase or sentence.  Arrange the reference list in numeric order as cited in the text. Include only one article per reference number. Abbreviate journal names according to NIH National Library of Medicine's List of Journals Indexed for Medline.

    6.1.  Reference style notes

    * If four or less authors, list all four; if greater than four, list first three followed by et al.
    * No periods after either author initials except for last author listed (e.g., Smith AJ, Blackstone JB.)
    * No commas between author surname and initial
    * No periods in abbreviations of journal title names
    * Volume and issue numbers should be unbolded; issue numbers should appear in parentheses immediately 
       after volume number
    * If article is not yet in print, provide year, volume, and doi number (2011;44. doi:xxxx)
    6.2. References should be cited as follows:

    6.2.1. Journals
    Nakaoki T, Mei Y, Miller LM,  et al. Candida antarctica lipase B catalyzed polymerization of lactones. Ind Biotechnol 2005;1(3):126-134.            

    6.2.2. Books
    Constable G and Somerville B. A Century of Innovation. Washington, DC: Joseph Henry Press, Washington, District of Columbia, 2001:25-36.

    6.2.3. Chapter in edited book
    Delagrave S et al. Combinatorial mutagenesis algorithms, digital imaging spectroscopy, and solid -phase assays for directed evolution. In: Svendsen A, ed. Enzyme Functionality. New York, NY:  Marcel Dekker, 2004:507-523.(2004).

    6.2.4. Websites
    U.S. Department of Energy. Breaking the Biological Barriers to Cellulosic Ethanol: A Joint Research Agenda. DOE/SC/EE-0095. (2006) Available at: http://genomicscience.energy.gov/biofuels (Last accessed June 2011).  Name of web page. Available at: Web address/URL. (Date last accessed)

    6.2.5.  Conference  presentations/papers/abstracts/posters
    Hess R. Feedstock assembly for a billion tons of biomass. In: First International Biorefinery Workshop (presentation). Washington, DC (July, 20-21, 2005).

    6.2.6. Unpublished source/Personal communication
    Provide researcher’s name and institution affiliation(s). (personal communication

    For included material published elsewhere, written permission is required from the publisher/producer concerned. This must be provided at time of manuscript submission. 

    Any other publications from which figures or tables are taken must be listed in the reference list. An appropriate credit line should be included in the relevant figure legend or table footnote.

    Page proofs are sent to corresponding authors via e-mail. Please ensure that any e-mail filters installed will accept messages from indbiotech.com and liebertpub.com domains.

    Once a paper has been accepted and edited, the corresponding author will receive page proofs. Because Industrial Biotechnology is a rapid-publication journal, editors request that page proofs containing corrections be returned to the Publisher within 484 hours of receipt. If the corresponding author expects to be unavailable at the time proofs are anticipated, please notify the Executive Editor and provide an alternate corresponding author and full contact information for that person (phone, fax, e-mail and physical mailing address). 

    §10-13. Other Peer-Review:


    Short Communications are concise presentations of peer-reviewed original research: adaptations or new applications of current tools, technologies, and methods, or new procedures or products of broader interest to the industrial biotechnology communities. The standard for originality of contribution to the research is relaxed compared to that for Original Research; however, scientific and/or commercial significance, and relevance to industrial biotechnology, must be clear. Short Communications should be between 1,000 and 2,000 words (not including a short abstract of 75 words or fewer) and contain a maximum of 6 graphics (including tables) and up to 20 references. Other than these stipulations, information in §2–9 pertains.

    11. REVIEWS
    A Review is a comprehensive, authoritative, scholarly survey of technologies, platforms, protocols, and literature. Industrial Biotechnology Reviews should be balanced, to focus beyond the research, product, or platform of a single company or laboratory, to contextualize all current, major technologies/discoveries in the particular area being reviewed (e.g., reviewers should indicate competitor products/platforms in discussions and/or tables or lists). Reviews should be broadly applicable to varied industrial biotechnology subsectors. Limit references to 100. All Reviews are subject to full peer-review.  Other than these stipulations, all relevant information in §2–9 pertains.

    12. METHODS
    Methods papers describe application of a particular technology or protocol, with supporting data clearly presented. Methods are now subject to peer-review. They are intended for rapid dissemination of current technologies, with intent to foster collaboration, client partnerships, and scientific dialogue. Methods papers should be data-rich; these are not marketing pieces. The strength of a particular technology or application should be apparent from the data itself. Methods pieces are generally between 1,000 and 2,000 words. Abstracts not required. Acronyms should be used and explained as appropriate. A maximum of 6 graphics is requested, including tables, and up to 25 references. Other than these stipulations, information in §2–9 pertains.

    §14-15. Non-Peer-Review (Trade editorial): 

    Feature Commentary articles are expert-authored pieces (1,000- to 3,000-words) about policy, funding, markets, business, legal issues, or science trends, of general relevance to the broad international readership in industrial biotechnology across various sectors. Figures are welcome though not required. A maximum of 30 references is requested. Commentaries are not subject to peer-review but may be informally reviewed by editorial board members with appropriate expertise.

    All Feature Commentaries are edited as per Industrial Biotechnology’s style guide. Authors receive page proofs for review before publication. 

    15. REPORTS
    Industrial Biotechnology publishes, in excerpt or whole, important industry, government, or institute reports from international sources on science and market trends and opportunities. All reports must be in the public domain, unless copyright permission is granted to GEN Publishing, Inc., and Mary Ann Liebert, Inc., publishers, for use in Industrial Biotechnology and related publications. All authors and sources are cited, with contact information, for potential purchasers of the full reports.

    16.  Disclosure Statement 
    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist." 

    17. REPRINTS
    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    Industrial Biotechnology is owned and published by GEN Publishing, Inc., a Mary Ann Liebert, Inc., company. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801. Phone: (914) 740-2100. Fax: (914) 740-2101.

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy

    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 




Recommended Publications

You may be interested in the following publications:

    Genetic Engineering & Biotechnology News

    Genetic Engineering & Biotechnology News

    The mostly widely-read publication covering tools, techniques, and technologies in the biotechnology industry.

    Environmental Engineering Science

    Environmental Engineering Science

    The authoritative peer-reviewed journal publishing state-of-the-art studies of innovative solutions to problems in air, water, and land contamination and waste disposal.

    The Journal of Record

    The Journal of Record

    A major voice in the sustainability community, the Journal documents the implementation of sustainability programs in higher education and business.

    Controversies in Science and Technology Volume 3:
    From Evolution to Energy

    Controversies in Science and Technology Volume 3:
    From Evolution to Energy

    Explores five more controversial scientific issues facing our world today: the social history of vaccines, evolution, food safety, biofuels, and nanotechnology.

    Biosecurity and Bioterrorism: Biodefense Strategy, Practice,
    and Science

    Biosecurity and Bioterrorism: Biodefense Strategy, Practice,
    and Science

    The peer-reviewed journal providing essential guidance for the protection of society against bioweapons, and is a key resource for policy makers, scientific experts, and government officials.

Browse All Publications »